NEW YORK (GenomeWeb) – Molecular diagnostics firm Great Basin Scientific announced today that the US Food and Drug Administration has granted 510(k) clearance for its Group B Streptococcus test.

The company plans a commercial launch of the GBS assay in the second quarter of 2015.

"Receiving FDA clearance for our GBS test represents a significant milestone for Great Basin, both as an expansion of our menu and as evidence of the company's ability to meet product deliverables," Great Basin CEO and Co-founder and CEO Ryan Ashton said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.